Hpgc Renmintongtai Pharmaceutical Corporation’s Net Profit Dropped 4.7% in 2022

Hpgc Renmintongtai Pharmaceutical Corporation (哈药集团人民同泰医药股份有限公司) (600829.SH) reported a net profit of 263.4 million yuan in 2022, down 4.7% year-on-year.

Meanwhile, the company posted 9.6 billion yuan in revenue, up 3.5% year-on-year.

At the end of the reporting period, it had 7.1 billion yuan in total assets and 4.6 billion yuan in total liabilities, with a liability-to-asset ratio of 65.1%.